HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) CME Activity Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Juweid, M. E. Search for Related Content PubMed PubMed Citation Articles by Juweid, M. E.

Radioimmunotherapy of B-Cell Non-Hodgkin’s Lymphoma: From Clinical Trials to Clinical Practice

Division of Nuclear Medicine, Department of Radiology, University of Iowa Hospitals and Clinics, Iowa City, Iowa

Radioimmunotherapy (RIT) is a new treatment modality for B-cell non-Hodgkin’s lymphoma (NHL). Recent clinical trials have clearly established its efficacy in NHL patients refractory to standard chemotherapy or immunotherapy with the widely used unconjugated rituximab monoclonal antibody (mAb). The Food and Drug Administration has approved ⁹⁰Y-ibritumomab tiuxetan anti-B-cell NHL mAb as the first commercially available radiolabeled antibody for cancer therapy. This comes only a few years after the introduction of rituximab into clinical practice as the first unconjugated antibody for cancer treatment, underscoring the success of both immunotherapy and RIT in the treatment of NHL. With the approval of ⁹⁰Y-ibritumomab tiuxetan, and based on the results of numerous clinical trials with radiolabeled anti-B-cell NHL mAbs, RIT promises to become integral to nuclear medicine practice. In this article, the basic concepts of RIT are reviewed with important milestones in its development for B-cell NHL treatment and particular emphasis on phase II and III clinical trials establishing its efficacy in clearly defined patient populations. Finally, the prospects for the expected widespread clinical use of RIT in the management of B-cell NHL, alone or in combination with other more established therapies, are discussed. This article provides both investigative and clinical nuclear medicine physicians with a better understanding of RIT capabilities and limitations in B-cell NHL and their role as consultants in the care of NHL patients.

Key Words: B-cell non-Hodgkin’s lymphoma • radioimmunotherapy • monoclonal antibodies

This article has been cited by other articles:

				R. Balhorn, S. Hok, P. A. Burke, F. C. Lightstone, M. Cosman, A. Zemla, G. Mirick, J. Perkins, A. Natarajan, M. Corzett, et al. Selective High-Affinity Ligand Antibody Mimics for Cancer Diagnosis and Therapy: Initial Application to Lymphoma/Leukemia Clin. Cancer Res., September 15, 2007; 13(18): 5621s - 5628s. [Abstract] [Full Text] [PDF]

				E. Mah and K. M. Spicer Comparison of Medium- and High-Energy Collimators for 131I-Tositumomab Dosimetry J. Nucl. Med. Technol., September 1, 2007; 35(3): 148 - 153. [Abstract] [Full Text] [PDF]

				H. Song, Y. Du, G. Sgouros, A. Prideaux, E. Frey, and R. L. Wahl Therapeutic Potential of 90Y- and 131I-Labeled Anti-CD20 Monoclonal Antibody in Treating Non-Hodgkin's Lymphoma with Pulmonary Involvement: A Monte Carlo-Based Dosimetric Analysis J. Nucl. Med., January 1, 2007; 48(1): 150 - 157. [Abstract] [Full Text] [PDF]

				H. K. Tan, R. W. Wassenaar, and W. Zeng Collimator Selection, Acquisition Speed, and Visual Assessment of 131I-Tositumomab Biodistribution in a Phantom Model J. Nucl. Med. Technol., December 1, 2006; 34(4): 224 - 227. [Abstract] [Full Text] [PDF]

				M. A. Meyer, S. Aliberti, G. Grignani, M. Aglietta, M. E. Juweid, and B. D. Cheson Positron-emission tomography in cancer therapy. N. Engl. J. Med., May 4, 2006; 354(18): 1958 - 1960. [Full Text] [PDF]

				K. J. Hamblett, P. D. Senter, D. F. Chace, M. M. C. Sun, J. Lenox, C. G. Cerveny, K. M. Kissler, S. X. Bernhardt, A. K. Kopcha, R. F. Zabinski, et al. Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate Clin. Cancer Res., October 15, 2004; 10(20): 7063 - 7070. [Abstract] [Full Text] [PDF]

				S. J. Horning, E. Weller, K. Kim, J. D. Earle, M. J. O'Connell, T. M. Habermann, and J. H. Glick Chemotherapy With or Without Radiotherapy in Limited-Stage Diffuse Aggressive Non-Hodgkin's Lymphoma: Eastern Cooperative Oncology Group Study 1484 J. Clin. Oncol., August 1, 2004; 22(15): 3032 - 3038. [Abstract] [Full Text] [PDF]

				S. Knop, A. Jakob, L. Kanz, H. Hebart, R. Bares, and B. Dohmen 186Rhenium-labeled anti-CD20 antibody radioimmunotherapy followed by autologous peripheral blood stem cell transplantation in patients with relapsed or refractory non-Hodgkin lymphoma Blood, February 1, 2004; 103(3): 1175 - 1175. [Full Text] [PDF]

				C. L. Hartmann Siantar, G. L. DeNardo, and S. J. DeNardo Impact of Nodal Regression on Radiation Dose for Lymphoma Patients After Radioimmunotherapy J. Nucl. Med., August 1, 2003; 44(8): 1322 - 1329. [Abstract] [Full Text] [PDF]